Hematologic Malignancy
Adult B Acute Lymphoblastic Leukemia
CI-CAN-00004348Explore in graph →
Hematologic12 active trials2 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004348Explore in graph →
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07313852 | A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 |
| clinicaltrials |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07277504 | Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07256353 | Allogeneic UCB-derived CAR-T for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | active not recruiting | Phase 2 | 24 | Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06696833 | Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04214886 | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 24 | Loyola UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03709719 | Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia(GRAALL-QUEST) | active not recruiting | Phase 2 | 95 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 3, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials